Tigermed sells associate stake for $34m
Hangzhou Tigermed Consulting has approved the sale of its entire 3.41% stake in Lishin Therapeutics (Shanghai) for $34.11 million.
The sale is part of a larger transaction where Lishin Therapeutics will transfer 95.09% of its equity to Chia Tai Pharmaceutical Investment (Beijing) Group.
Tigermed acquired its initial stake in Lishin Therapeutics in December 2019, with additional investments in May and November 2020. The divestment aims to increase cash flow and support the company's development.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Hangzhou Tigermed Consulting publishes news
Free account required • Unsubscribe anytime